|
業務類別
|
-- |
|
業務概覽
|
Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden. |
| 公司地址
| Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105 |
| 電話號碼
| +46 187808800 |
| 傳真號碼
| +46 187808888 |
| 公司網頁
| https://www.orexo.com |
| 員工數量
| 110 |
| Mr. Fredrik Jarrsten |
Executive Vice President and Chief Financial Officer |
-- |
02/04/2025 |
| Mr. Nikolaj Sorensen |
Chief Executive Officer and President |
-- |
02/04/2025 |
|
|
| Mr. James Julian Noble, M.A. |
Chairman of the Board |
02/04/2025 |
| Ms. Christine Rankin |
Independent Director |
02/04/2025 |
| Mr. Robin Evers |
Director |
02/04/2025 |
| Mr. G. Frederick Wilkinson |
Independent Director |
02/04/2025 |
| Mr. Staffan Lindstrand |
Independent Director |
02/04/2025 |
| Dr. Friedrich von Bohlen und Halbach, PhD |
Independent Director |
02/04/2025 |
|
|
|
|
